Haemonetics Reports $1.334 Billion Revenue with 2% Decrease, Strategic Acquisitions and Stock Repurchase Announced

Haemonetics Corporation reported a net revenue of $1.334 billion for the fiscal year ending March 28, 2026, reflecting a 2% decrease from the previous year’s revenue of $1.361 billion. The decline was attributed primarily to the transition of customer relationships in the Plasma and Blood Center segments, which accounted for approximately $153 million in nonrecurring revenue in fiscal 2025. Despite this decrease, the Hospital segment saw growth, particularly in the Hemostasis Management and Transfusion Management product lines, contributing to an overall operating income of $156.7 million, down 29.3% from $221.8 million in fiscal 2025.

The company’s Plasma segment generated $524.5 million in revenue, a 2% decrease from $535.4 million in the prior year, while the Blood Center segment experienced a more significant decline, with revenues falling 15.3% to $221.3 million, largely due to the divestiture of the Whole Blood product line. In contrast, the Hospital segment reported a revenue increase of 4.3%, reaching $588.3 million, driven by higher sales volumes and market expansion. The company’s gross profit improved by 5.2% to $787.6 million, resulting in a gross margin of 59%, up from 55% in the previous year.

Strategically, Haemonetics made significant moves in fiscal 2026, including the acquisition of Vivasure Medical for $164.4 million, which is expected to enhance its Hospital business unit by adding innovative percutaneous vessel closure technology. The company also repurchased $175 million of its common stock during the fiscal year as part of its ongoing share repurchase program, which has a remaining authorization of $325 million. Additionally, Haemonetics repaid $300 million in convertible senior notes that matured in March 2026, funded through cash on hand and borrowings from its revolving credit facility.

Operationally, Haemonetics employed approximately 3,009 individuals as of March 28, 2026, with a focus on enhancing its workforce through training and development initiatives. The company reported a current ratio of 3.0, indicating strong liquidity, and a net debt position of $(979.1 million), reflecting its cash reserves exceeding total debt. Looking ahead, Haemonetics anticipates continued growth in its Plasma and Hospital segments, driven by ongoing product innovation and strategic investments, despite facing challenges in the Blood Center market due to declining transfusion rates and increased competition.